---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013368"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T02:01:04.501100+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma presents KROS101 preclinical data at ASCO; shows superiority over TRX518

## Summary
- KROS101 is a small molecule GITR ligand agonist with dual mechanisms: promotes T effector proliferation and reduces T reg suppression.
- Preclinical study showed KROS101 enhanced T cell cytotoxicity and cytokine production, boosting tumor cell killing.
- KROS101 was superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg reduction, and preventing T cell exhaustion.
- CEO Dr. John Yu presented findings at ASCO 2025 (May 30-June 3) and expressed strong support for continued study of KROS101.

## SEC filing metadata
- accession: 0001641172-25-013368
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000164117225013368/0001641172-25-013368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000164117225013368/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013368
- JSON: https://secwatch.observer/filing/0001641172-25-013368.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013368.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.